Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA
Executive Summary
Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.